What are Cap-dependent endonuclease inhibitor drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cap-dependent endonuclease inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Influenza PA endonuclease). 0 are currently marketed, with 2 more in clinical development.

Cap-dependent endonuclease inhibitor

0 marketed 2 in Phase 3

This page covers all Cap-dependent endonuclease inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Influenza PA endonuclease, Influenza virus PA endonuclease (cap-dependent endonuclease).

Targets

Influenza PA endonuclease · Influenza virus PA endonuclease (cap-dependent endonuclease)

Phase 3 pipeline (2)

Baloxavir Marboxil tablets · Jiaxing AnDiCon Biotech Co.,Ltd · Virology/Infectious Disease
Baloxavir marboxil inhibits the influenza virus endonuclease, blocking viral cap-dependent transcription and preventing viral replication.
Placebo to Baloxavir Marboxil · Shionogi · Infectious Disease / Virology
Baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks influenza virus polymerase, preventing viral mRNA synthesis and replication.

Patent intelligence

cap dependent endonuclease inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates